Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

39.16 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

3 Low-Volatility Stocks We Find Risky

November 16, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

November 12, 2025

Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%.

Via StockStory

Topics Stocks Supply Chain

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

How Do Investors Really Feel About Royalty Pharma? ↗

September 16, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗

November 05, 2025

Royalty Pharma's Q3 2025 earnings beat estimates, with strong revenue and EPS. The company also raised its full-year 2025 guidance.

Via Chartmill

Topics Earnings

Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2

November 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings

November 03, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗

November 01, 2025

RPRX stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout above key resistance.

Via Chartmill

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗

October 31, 2025

Via MarketBeat

2 Reasons to Avoid RPRX and 1 Stock to Buy Instead

October 29, 2025

While the S&P 500 is up 23.9% since April 2025, Royalty Pharma (currently trading at $36.80 per share) has lagged behind, posting a return of 12.5%. This was partly due to its softer quarterly results...

Via StockStory

Topics Government Stocks Supply Chain

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗

October 28, 2025

Via MarketBeat

3 Healthcare Stocks We Keep Off Our Radar

October 13, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...

Via StockStory

Topics Economy Stocks

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

September 17, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges

September 08, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

Topics Economy

1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off

August 29, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

1 Value Stock with Exciting Potential and 2 We Avoid

August 25, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings ↗

August 15, 2025

Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks.

Via Chartmill

1 Healthcare Stock for Long-Term Investors and 2 We Ignore

August 15, 2025

Via StockStory

Topics Stocks

Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today ↗

August 12, 2025

Via Benzinga

RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments

August 12, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14...

Via StockStory

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)

August 10, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Royalty Pharma (RPRX) Q2 Receipts Up 20% ↗

August 06, 2025

Via The Motley Fool

Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance ↗

August 06, 2025

Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence.

Via Chartmill

Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates

August 06, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per...

Via StockStory

Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow

August 04, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for.

Via StockStory

Topics Government World Trade

2 Reasons to Watch RPRX and 1 to Stay Cautious

July 30, 2025

Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.